OBI Pharma Discontinues Phase 1/2 Study Of Antibody-OBI 888

OBI Pharma, a Taiwan biopharma company, said it has discontinued the phase 1/2 Study for OBI 888, a Globo H antibody.

According to the company, preliminary data from phase 1/2 study demonstrated that OBI 888 is a safe and well tolerated product and showed some trends of efficacy. However, due to the higher antibody amount required for the OBI-888 treatment compared to the ADC, OBI-999, and an unexpected low drug yield at the large manufacturing scale, OBI-888 no longer fulfills goal of developing cost-effective therapies for cancer patients.

The company said it will focus on novel cancer pipeline under phase 3 (Adagloxad Simolenin-vaccine) and phase 2 (OBI 999-ADC, OBI 833-vaccine and OBI 3424-small molecule) clinical development.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Walt Disney's streaming service Disney+ is rolling out its much-anticipated new ad-supported subscription plan for Disney+ in the U.S. as part of its bid to stem the loss and make its streaming business profitable after the services posted a hefty operating loss of more than $1 billion in the third quarter. It is also raising pricing for its bundled subscription plans with Hulu, ESPN+ and live TV. The U.S. Food and Drug Administration announced the intended availability of base powder to make around 6 million bottles of specialty formula from Mexico as part of its efforts to meet the nationwide supply shortage caused by Abbott Nutrition recall. Reckitt Nutrition/Mead Johnson Nutrition will send an initial shipment of 331 thousand pounds of base powder for PurAmino Hypoallergenic Formula. Shares of Deutsche Telekom AG were gaining more than 1 percent in the morning trading in Germany after the telecom major on Thursday raised its fiscal 2022 earnings outlook again, despite reporting lower profit in its second quarter. Adjusted EBITDA AL, a key earnings metric, increased, while adjusted EBITDA AL margin dropped.
Follow RTT